Talphera Q3 2026 Earnings Date & Estimates

Talphera (NASDAQ:TLPH) is a specialty pharmaceutical company focused on developing and commercializing therapies for the management of acute pain. The company’s products are designed for use in medically supervised settings, including hospitals and other healthcare environments where rapid, noninvasive pain relief may be needed.

Talphera’s principal product is DSUVIA, a sublingual tablet containing sufentanil. The product was approved by the U.S. Food and Drug Administration in 2018 for the management of acute pain in adults in certified medically supervised healthcare settings. DSUVIA is administered under the supervision of a healthcare professional and is intended for short-term use when an intravenous route is not practical.

The company was formerly known as AcelRx Pharmaceuticals, Inc. and adopted the Talphera name as part of its focus on acute-pain therapies. Its operations and regulatory activities have primarily centered on the United States, with earlier development and commercialization efforts also involving Europe. Talphera is headquartered in the United States and has been led by Vincent Angotti as chief executive officer.